Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4278589 | 0.99 | BACE1 (0.72) | BACE1 | |
| SCHEMBL2381538 | 0.84 | BACE1 (1.00) | BACE1 | |
| SCHEMBL908174 | 0.84 | BACE1 (1.00) | BACE1 | |
| SCHEMBL4137250 | 0.83 | BACE1 (0.87) | BACE1 | |
| SCHEMBL4142180 | 0.83 | BACE1 (0.90) | BACE1 | |
| SCHEMBL4143303 | 0.83 | BACE1 (1.00) | BACE1 | |
| SCHEMBL27702187 | 0.83 | BACE1 (0.76) | BACE1 | |
| SCHEMBL4159486 | 0.83 | BACE1 (0.79) | BACE1 | |
| SCHEMBL4137587 | 0.81 | BACE1 (0.84) | BACE1 | |
| SCHEMBL27742935 | 0.80 | BACE1 (0.47) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | ASTEX THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099217-A1 | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies | PSEN2, APP, PSEN1 | BACE1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.